BioTuesdays

Tag - Sean Lee

Virios Therapeutics
Markets

HCW starts Virios Therapeutics at buy; PT $12

H.C. Wainwright initiated coverage of Virios Therapeutics (NASDAQ:VIRI) with a “buy” rating and price target of $12. The stock closed at $4.58 on Dec. 14. Virios is a clinical-stage biotech company developing a novel...

December 15, 2021
Kazia
Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021